Latest News Releases Keyword Search Year None2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996 3/21/23 Neurocrine Biosciences to Present at the Stifel 2023 CNS Days 3/9/23 Neurocrine Biosciences Announces Results from the Real-World RE-KINECT™ Study Published in the Journal of Patient-Reported Outcomes Demonstrating the Effects of Possible Tardive Dyskinesia (TD) on Patient Health and Social Functioning 3/9/23 Neurocrine Biosciences Presents Data on In Vitro Dissolution Performance of INGREZZA® (valbenazine) Capsule Contents via Soft Foods or Feeding Tube at AMDA - PALTC 2023 Annual Conference 3/8/23 Neurocrine Biosciences to Participate at Investor Conferences in March 3/3/23 Neurocrine Biosciences Presents Data on Improvements Over Time with Long-Term Use of INGREZZA® (valbenazine) Capsules in Older and Elderly Patients at the American Association for Geriatric Psychiatry 2023 Annual Meeting 2/7/23 Neurocrine Biosciences to Present at the SVB Securities Global Biopharma Conference 2/6/23 Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2022 Financial Results and Provides Financial Expectations for 2023 1/17/23 Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial Results 1/9/23 Neurocrine Biosciences and Voyager Therapeutics Enter Strategic Collaboration for Development and Commercialization of Voyager’s GBA1 Program and Other Next-Generation Gene Therapies for Neurological Diseases 1/3/23 Neurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
